glaucoma

Novel therapies abound in pipelineThe importance of novel therapies for ocular disease is a given. However, as most novel therapies are financed by the private sector, it is fortunate that investors find ophthalmology a worthwhile investment.
Novel glaucoma drug lowers IOP by unique combination of mechanismsIn a study of normal volunteers, once-daily dosing of netarsudil mesylate ophthalmic solution 0.02% lowered IOP relative to baseline by increasing outflow facility and decreasing episcleral venous pressure.
Glaucoma monitoring implant receives CE markAn implantable glaucoma sensor has received CE mark approval for marketing in the European Union. The sensor (Eyemate, Implandata Ophthalmic Products) can provide frequent IOP readings, informing patients and their physicians about how the pressure changes by time of day and from one day to another.
POAG: Enigmatic group of heterogenous diseases?Various subtypes of primary open-angle glaucoma might exist. Continued research is needed to identify the characteristics of each subtype for better management.
New concepts in diagnosis and treatmentIn the past decade, several significant advancements have been made in the arena of glaucoma diagnosis. Spectral domain optical coherence tomography (SD-OCT), newer algorithms in trend analysis of visual field studies, and combined visually evoked potential (VEP) and pattern electroretinography (ERG) studies have been the hallmarks of such recent advancements.
NICE recommends dexamethasone adalimumab for uveitisThe UK’s National Institute for Health and Care Excellence (NICE) has given preliminary approval to dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) and adalimumab (Humira, AbbVie) for sight-threatening non-infectious posterior uveitis.
Novel glaucoma treatments factor in scleral behaviorInnovations in sustained-drug delivery and neuroprotection are bringing glaucoma specialists one step closer to additional therapeutic options.
Researchers image single cell deaths in glaucoma patientsA new imaging technique can show the deaths of individual cells in people with glaucoma by labelling the cells with fluorescent dye, according to researchers. The approach might eventually be used to diagnosis the disease in its early stages or measure its progression.
Optimizing CPC treatment outcomes with built-in transilluminationA new probe offers combined transillumination and laser fiber for targeted transscleral cyclophotocoagulation. Steven D. Vold, MD, shares some of his clinical experience.
Growing attention turns to cerebrospinal fluid pressure in glaucomaCataract surgery in patients with coexisting uveitis is more challenging than managing either condition alone.